Ratings Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-05-14 am EDT			5-day change	1st Jan Change
21 ^HKD	+0.48%		+12.18%	-23.08%

Apr. 25	Ascentage Pharma to Present Four Studies at US Oncology Meet	MT
Apr. 09	Ascentage Pharma Chairman Boosts Stake in Firm	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ASCENTAGE PHARMA GROUP INTERNATIONAL	-23.08%	761M	-
VERTEX PHARMACEUTICALS INCORPORATED	+4.81%	111B	B+
REGENERON PHARMACEUTICALS, INC.	+12.13%	105B	B+
BIONTECH SE	-12.55%	22.34B	B+
ARGENX SE	-3.70%	21.93B	B
GENMAB A/S	-6.03%	18.59B	A-
WUXI APPTEC CO., LTD.	-35.21%	18.12B	A-
BEIGENE, LTD.	-10.59%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+4.17%	13.7B	C+
SAREPTA THERAPEUTICS, INC.	+37.03%	12.45B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes